Over the last decades, the incidence of type 2 diabetes (T2D) is increasing substantially. Emerging evidences from epidemiological studies have shown the association between higher intake of soy isoflavones and reduced risk of T2D and its associated health risks. Daidzein, a soy isoflavone, has been found to have a promising therapeutic potential in managing T2D pathophysiology. Fermented soybean is the major source of daidzein; however, it can also be formed via the consumption of its glycosylated moiety, daidzin with subsequent hydrolysis by intestinal bacterial enzyme. Many studies reported the prophylactic effect of daidzein on the improvement of hyperglycemia, insulin resistance, dislipidemia, obesity, inflammation, and other complications associated with T2D. The molecular mechanisms underlying the action of daidzein include diverged pathways where daidzein has been shown to interact with several signaling molecules and receptors to achieve desirable effect. Although the specific molecular mechanism is still elusive, further studies are thus needed to understand it in detail. In this review, we discuss the antidiabetic potential of daidzein with respect to the evidences from various clinical, preclinical, and cell culture studies and the underlying molecular mechanism in a precise way to have a comprehensive account on this isoflavone with promising therapeutic potential. © 2018 BioFactors, 44(5):407–417, 2018

中文翻译：

---

大豆黄酮，其对葡萄糖和脂质代谢受损以及与 2 型糖尿病相关的血管炎症的影响。


在过去的几十年里，2 型糖尿病 (T2D) 的发病率大幅增加。流行病学研究的新证据表明，较高的大豆异黄酮摄入量与降低 T2D 风险及其相关健康风险之间存在关联。大豆异黄酮 (Daidzein) 是一种大豆异黄酮，已被发现在控制 T2D 病理生理学方面具有良好的治疗潜力。发酵大豆是大豆黄酮的主要来源；然而，它也可以通过消耗其糖基化部分黄豆甙并随后被肠道细菌酶水解而形成。许多研究报道了大豆黄酮对改善高血糖、胰岛素抵抗、血脂异常、肥胖、炎症和其他与 T2D 相关的并发症的预防作用。大豆苷元作用的分子机制包括不同的途径，其中大豆苷元已被证明与几种信号分子和受体相互作用以达到理想的效果。尽管具体的分子机制仍然难以捉摸，但仍需要进一步的研究来详细了解它。在这篇综述中，我们根据各种临床、临床前和细胞培养研究的证据以及潜在的分子机制，以精确的方式讨论了大豆黄酮的抗糖尿病潜力，以全面阐述这种具有良好治疗潜力的异黄酮。 © 2018 生物因素，44(5):407–417, 2018